Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HALSEY WITHDRAWAL OF FOUR PENDING ANDAs

Executive Summary

HALSEY WITHDRAWAL OF FOUR PENDING ANDAs due to "possible falsification of documents" is the subject of an Oct. 24 letter from Rep. Dingell (D-Mich.) to FDA Acting Commissioner James Benson. Dingell's letter states that his House Oversight Subcommittee "has been advised that Halsey Drug Co., Inc....has withdrawn four pending ANDAs because of records discrepancies and possible falsification of documents." Reportedly, the problems uncovered by FDA inspections of the Brooklyn--based firm involve batch-size problems and reconstructed raw material cards not in conformance with batch sizes. The agency is said to be considering referral of its findings to the Justice Department for prosecution. Dingell asked FDA to "provide the subcommittee with all documents and records referring or relating to the discrepancies and possible falsification at Halsey, and a list of Halsey employees or ex-employees (and their counsel, if any) with knowledge of these matters." FDA is asked to provide the information by Nov. 5. Last year FDA filed a 10-item FD-483 inspection report focusing mainly on Halsey's recordkeeping. Citations included absence of records to account for discrepancies between the actual yield of a batch and the number of capsules in house. FDA's review of five ANDAs resulted in no findings of fraud by the agency, Halsey said. That inspection, conducted from Aug. 23, 1989 to Oct. 11, 1989, was part of FDA's investigation of the 20 largest generic firms following disclosure of the generic drug scandal ("The Pink Sheet" Dec. 11, 1989, p. 7).

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS018321

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel